ロード中...
Preliminary study highlights the potential of immune checkpoint inhibitors in sarcomatoid mesothelioma
BACKGROUND: Malignant pleural mesothelioma (MPM) is well known as an aggressive disease with poor survival. This has sparked trials of alternate immune-based therapies in MPM. While up to a quarter of MPM patients respond to immune checkpoint inhibitors (ICIs), predicting response remains challengin...
保存先:
| 出版年: | Transl Lung Cancer Res |
|---|---|
| 主要な著者: | , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
AME Publishing Company
2020
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7354134/ https://ncbi.nlm.nih.gov/pubmed/32676326 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.21037/tlcr-19-485 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|